Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
by Zacks Equity Research
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy
by Zacks Equity Research
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.
Biogen Cracks the Case With AbbVie for Humira Biosimilar
by Zacks Equity Research
Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.
Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus
by Zacks Equity Research
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
Pfizer's Lung Cancer Candidate Gets FDA's Priority Review
by Zacks Equity Research
Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.
Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale
by Zacks Equity Research
Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife
The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources
Top Research Reports for Facebook, UnitedHealth & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), UnitedHealth (UNH) and Pfizer (PFE).
Alnylam Falls on Pfizer's Rare Disease Drug Success
by Zacks Equity Research
Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.
Shire's Stock Continues to Rise as Takeda Sets Eyes On it
by Zacks Equity Research
Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.
Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease
by Zacks Equity Research
Amgen's (AMGN) leukemia drug, Blincyto is the first approved drug for the treatment of minimal residual disease in the United States.
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
5 Juicy Dividend Stocks to Ride Out a Dicey April
by Tirthankar Chakraborty
April is historically the second best month of the year, but there are ample reasons why it could be cruel this year.
Tackle Market Uncertainty With These 3 Quality Dividend ETFs
by Zacks Equity Research
Consider these three dividend ETFs for your portfolio to fight growing market uncertainty.
Is a Recession in the Cards? 4 Safe Bets for Your Portfolio
by Indrajit Bandyopadhyay
After nearly a decade of the global financial crisis of 2007-2008, some analysts believe that the threat of another recession lurks. However, the time and its impact is yet to be ascertained.
Merck KGaA's Tepotinib Gets Fast Track Designation in Japan
by Zacks Equity Research
Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.
Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV
by Zacks Equity Research
Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.
4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End
by Kinjel Shah
The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying
Pfizer's Chantix Fails in Phase IV Study in Young Smokers
by Zacks Equity Research
Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.
Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod
by Zacks Equity Research
Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.
Wall Street Braces for Ugliest March: 5 Ultra-Safe Picks
by Tirthankar Chakraborty
The Dow is on track for its worst March in nearly 40 years, while the month is likely to be most awful for the S&P 500 and the Nasdaq since 2001.
Novartis Gets Positive CHMP Opinion on Biosimilar Remicade
by Zacks Equity Research
The CHMP gave a positive opinion to Novartis (NVS) proposed biosimilar of Remicade for all of the branded drug's indications. A decision from the EMA is expected shortly.
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
by Zacks Equity Research
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.